Heart failure: Not enough pump iron? by McMurray, John J. V. & Ponikowski, Piotr P.
s
m
i
J
Journal of the American College of Cardiology Vol. 58, No. 5, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.066EDITORIAL COMMENT
Heart Failure
Not Enough Pump Iron?*
John McMurray, MD,†
Piotr Ponikowski, MD, PHD‡
Glasgow, Scotland, United Kingdom;
and Wroclaw, Poland
The intriguing study of Maeder et al. (1) further shifts
the focus on anemia in heart failure away from hemoglo-
bin and towards iron. Indeed, the prevalence and poten-
tial importance of iron deficiency per se, irrespective of
hemoglobin, is a subject of intense interest in heart
failure at present (2– 6). Because there are no agreed-
upon criteria for the diagnosis of iron deficiency, preva-
lence varies widely (7). However, 1 study, using the “gold
tandard” of bone marrow iron staining, reported that as
any as 73% of patients with advanced heart failure had
ron deficiency (8). Using alternative diagnostic criteria,
ankowska et al. (3) recently showed that iron deficiency
in patients with heart failure was associated with a
significantly worse prognosis, independent of anemia.
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The current study adds further evidence to an emerging
picture that paints an important role for iron deficiency in
heart failure (1). The key, new findings of Maeder et al.
are the demonstration of reduced iron content and
transferring receptor 1 (Tfr1) expression in the myocar-
dium of patients with heart failure, compared with
controls, and the finding that Tfr1 expression is regu-
lated, experimentally, by beta adrenoceptor agonists and
aldosterone (although not natriuretic peptides). The first
of these findings has resonance with experimental studies
in animals that showed that induction of iron deficiency
leads to myocardial hypertrophy and, eventually, the devel-
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to play a role in the changes in these experimental models,
linking to the second finding of Maeder et al. (1). It is,
therefore, tempting to speculate that myocardial iron
depletion, perhaps caused by neurohumorally mediated
Tfr1 down-regulation, contributes to decline in systolic
function and clinical progression in patients with heart
failure (10). This is pathophysiologically plausible, given
the crucial role that iron plays in cellular function in
general and oxidative metabolism in particular, especially
in metabolically active tissue (4). Although attractive,
this hypothesis needs further testing. The number of
individuals studies by Maeder et al. (1) was small (myo-
cardial samples were obtained from 6 explanted failing
hearts and 5 unused donor hearts). The comparison was
extreme, that is, healthy heart muscle was compared with
that from patients with end-stage heart failure undergo-
ing transplantation. The subjects studied were also far
from typical—the average patient age was 46 years, and
the donor hearts were from even younger individuals. The
experimental studies of Tfr1 regulation were also conducted
in cardiomyocytes from young rats and with high concen-
trations of adrenoceptor agonists and aldosterone.
So, what could be done to test this intriguing new
hypothesis? Three thoughts come to mind. First, it may be
possible to adapt new magnetic resonance imaging tech-
niques, currently used to identify myocardial overload, to
detect iron depletion (11). This would allow noninvasive
verification of the current findings. Second, the potential
role of beta-adrenoceptors and aldosterone in mediating
myocardial iron deficiency by down-regulating Tfr1 could
be tested with the same imaging approach, if viable, using
beta-blockers and aldosterone antagonists. Last, the effect of
iron replenishment on ventricular structure and function
could be examined. With respect to the latter idea, there is
already preliminary evidence that iron supplementation of
deficient patients may improve exercise performance, New
York Heart Association functional class, and a number of
patient-reported outcomes (12).
Doubtless this story will turn out to be more complex
than outlined. Iron deficiency and anemia are inextricably
linked, and dissecting out the pathophysiological role (if
any) played by iron deficiency versus anemia (and dimin-
ished oxygen delivery) per se is difficult (7). The contribu-
tion of regulators of iron metabolism, such as hepcidin and
hypoxia inducible factor, which may be present in the
myocardium and have a variety of actions, is currently
uncertain (9,13). Another of these, erythropoietin, is being
tested as a treatment in a trial of anemia correction in heart
failure, which is presently underway (14).
One thing is clear. The novel and interesting findings of
Maeder et al. (1) must now make cardiologists think about
the possibility that iron depletion, as well as iron overload,
might lead to myocardial dysfunction (15).
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